Aralez Pharma (ARLZ) Misses Q4 EPS by 12c; Announces Resubmission of YOSPRALA NDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Aralez Pharma (ARLZ) Misses Q4 EPS by 12c; Announces Resubmission of YOSPRALA NDA
March 15, 2016 7:00 AM EDT
- Announced Today the Resubmission to the FDA of the NDA for YOSPRALA-
- Expects 2016 Net Revenues to be in a Range of $48 Million to $58 Million-
MILTON, Ontario, March 15, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced results for the fourth quarter and full-year ended December 31, 2015. The Company also highlighted important corporate, commercial, and regulatory updates. All figures are in U.S.... More
March 15, 2016 6:30 AM EDT
MILTON, Ontario, March 15, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration ("FDA") the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
Secondary prevention with aspirin may be recommended in patients who have had a myocardial infarction or unstable angina pectoris, chronic stable angina... More
